Search Results for: 19

Synthetic Biologics Reports Second Quarter 2012 Financial Results

— Addition of Monoclonal Antibodies for Infectious Diseases Emphasizes Focus on Synthetic Biologics — ANN ARBOR, Mich., Aug. 14, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for unmet medical needs, today reported financial results for the three and six months ended June 30, 2012 and […]

Synthetic Biologics Reports Second Quarter 2012 Financial Results Read More »

Synthetic Biologics Reports First Quarter 2012 Financial Results

— Preclinical and Clinical Programs Moving Forward — ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights. Operational Highlights Management Team –

Synthetic Biologics Reports First Quarter 2012 Financial Results Read More »

Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director

— Gene Therapy Veteran to Enhance Company’s DNA-Based Therapeutic Development — ANN ARBOR, Mich., April 18, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Michael Kaleko, M.D., Ph.D., has joined the Company as Scientific Director. Dr. Kaleko has worked

Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director Read More »

Synthetic Biologics Reports 2011 Year End Financial Results

— Company Prioritizes Focus on Synthetic DNA-Based Therapeutics — ANN ARBOR, Mich., March 30, 2012 /PRNewswire/ — Synthetic Biologics, Inc.  (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported  financial results for the year ended December 31, 2011 and summarized operational highlights. Operational Highlights Synthetic Biologics

Synthetic Biologics Reports 2011 Year End Financial Results Read More »